Drug Profile

SP 0268

Alternative Names: Acne mRNA vaccine - Sanofi; SP-0268

Latest Information Update: 19 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi
Class RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Acne

Most Recent Events

11 Aug 2026 Sanofi plans a phase II trial for Acne (In adolescents) in October 2026 (IM, Injection) (NCT07756957)
03 Jul 2025 Sanofi initiates phase I/II trial for Acne in USA (IM) (NCT07013747)
06 Jun 2025 Sanofi Pasteur plans phase-I/II trial for Acne (In adults) (IM, Suspension) (NCT07013747)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com